Artelo Biosciences R&D Spending Growth & History (ARTL)
Artelo Biosciences's r&d spending was $5.4M for fiscal 2025.
View full Artelo Biosciences company overviewArtelo Biosciences annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.4M | −$570,000 | −9.51% |
| 2024 | 2024-12-31 | $6.0M | $297,000 | +5.21% |
| 2023 | 2023-12-31 | $5.7M | $1.4M | +31.73% |
| 2022 | 2022-12-31 | $4.3M | $540,000 | +14.27% |
| 2021 · Dec 31 | 2021-12-31 | $3.8M | — | — |
| 2021 · Aug 31 | 2021-08-31 | $2.8M | $920,000 | +47.94% |
| 2020 | 2020-08-31 | $1.9M | $827,008 | +75.73% |
| 2019 | 2019-08-31 | $1.1M | −$157,862 | −12.63% |
| 2018 | 2018-08-31 | $1.2M | — | — |
Artelo Biosciences quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $876,000 | −$995,000 | −53.18% |
| Q1 2026 | 2026-03-31 | $773,000 | −$611,000 | −44.15% |
| Q4 2025 | 2025-12-31 | $893,000 | −$1.6M | −63.93% |
| Q3 2025 | 2025-09-30 | $1.3M | $950,000 | +292.31% |
| Q2 2025 | 2025-06-30 | $1.9M | $186,000 | +11.04% |
| Q1 2025 | 2025-03-31 | $1.4M | −$123,000 | −8.16% |
| Q4 2024 | 2024-12-31 | $2.5M | $352,000 | +16.57% |
| Q3 2024 | 2024-09-30 | $325,000 | −$1.3M | −79.50% |
| Q2 2024 | 2024-06-30 | $1.7M | $933,000 | +124.07% |
| Q1 2024 | 2024-03-31 | $1.5M | $272,000 | +22.02% |
| Q4 2023 | 2023-12-31 | $2.1M | $398,000 | +23.06% |
| Q3 2023 | 2023-09-30 | $1.6M | $507,000 | +47.03% |
| Q2 2023 | 2023-06-30 | $752,000 | −$304,000 | −28.79% |
| Q1 2023 | 2023-03-31 | $1.2M | $771,000 | +166.16% |
| Q4 2022 | 2022-12-31 | $1.7M | — | — |
| Q3 2022 | 2022-09-30 | $1.1M | $44,000 | +4.26% |
| Q2 2022 | 2022-06-30 | $1.1M | $86,000 | +8.87% |
| Q1 2022 · Mar 31 | 2022-03-31 | $464,000 | $157,000 | +51.14% |
| Q1 2022 · Nov 30 | 2021-11-30 | $1.3M | $678,000 | +113.95% |
| Q3 2021 · Sep 30 | 2021-09-30 | $1.0M | — | — |
| Q3 2021 · Jun 30 | 2021-06-30 | $970,000 | — | — |
| Q3 2021 · May 31 | 2021-05-31 | $951,204 | $692,528 | +267.72% |
| Q2 2021 · Mar 31 | 2021-03-31 | $307,000 | — | — |
| Q2 2021 · Feb 28 | 2021-02-28 | $663,359 | −$57,947 | −8.03% |
| Q1 2021 | 2020-11-30 | $595,000 | −$71,938 | −10.79% |
| Q4 2020 | 2020-08-31 | $272,080 | $38,312 | +16.39% |
| Q3 2020 | 2020-05-31 | $258,676 | $74,472 | +40.43% |
| Q2 2020 | 2020-02-29 | $721,306 | $231,325 | +47.21% |
| Q1 2020 | 2019-11-30 | $666,938 | $482,899 | +262.39% |
| Q4 2019 | 2019-08-31 | $233,768 | −$98,698 | −29.69% |
| Q3 2019 | 2019-05-31 | $184,204 | −$52,641 | −22.23% |
| Q2 2019 | 2019-02-28 | $489,981 | −$157,486 | −24.32% |
| Q1 2019 | 2018-11-30 | $184,039 | $150,963 | +456.41% |
| Q4 2018 | 2018-08-31 | $332,466 | — | — |
| Q3 2018 | 2018-05-31 | $236,845 | — | — |
| Q2 2018 | 2018-02-28 | $647,467 | — | — |
| Q1 2018 | 2017-11-30 | $33,076 | — | — |
Artelo Biosciences r&d spending trends
Between the periods ended 2018-08-31 and 2025-12-31, Artelo Biosciences's r&d spending increased from $1.2M to $5.4M, a change of $4.2M. The latest reported quarter, Q2 2026, shows $876,000.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Artelo Biosciences source filings ↗